Quantcast

Industry news that matters to you.  Learn more

Biomarker Promise for Parkinson’s Disease

Reliable biomarkers that can be used for early diagnosis and tracking disease progression are the cornerstone of research into disease-modifying treatments for neurodegenerative diseases. Although important strides have been made in biomarker research, for Parkinson’s disease (PD) as for other diseases, no validated, inexpensive, and simple markers are available. The launch of the Parkinson’s Progression Markers Initiative (PPMI), a public-private partnership spearheaded by the Michael J. Fox Foundation that aims to identify clinical, imaging, and biological markers of disease progression is therefore welcome news. But what do patients and the research community stand to gain from this initiative and can it fullfil its promise?